Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 and Viagra | A Comprehensive Comparison

Curious about how PT-141 and Viagra work together? Inside, researchers will find everything they must know about these potent compounds. A peptide analog of α-Melanocyte-stimulating hormone (α-MSH), PT-141 has been approved as bremelanotide by the United State

Curious about how PT-141 and Viagra work together?

Inside, researchers will find everything they must know about these potent compounds.

A peptide analog of α-Melanocyte-stimulating hormone (α-MSH), PT-141 has been approved as bremelanotide by the United States Food and Drug Administration (FDA) for treating libido issues in women.

Researchers are now studying PT-141 for its potential to treat sexual dysfunction in men, including erectile dysfunction (ED) and low libido.

Stil, the most popular medication today for treating erectile dysfunction is sildenafil. Known more commonly as Viagra, it has been available as a prescription medication in the US for over two decades. It is used to maintain and increase erection strength, namely in older men.

Researchers specializing in male sexual disorders may be curious as to:

How both PT-141 and Viagra interact with each other?

Is it safe to combine PT-141 and Viagra?

Is PT-141 better than Viagra in the context of male sexual health?

We have provided extensive information in this guide to answer these questions and more.

Buy PT-141 from our top-rated vendor...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is PT-141?

Also known as bremelanotide, PT-141 is a synthetic melanocortin receptor agonist approved in 2019 by the US FDA for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1, 2].

Chemically, it is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and a derivative of the synthetic melanocortin melanotan 2. It acts by binding to receptors of the melanocortin family, namely melanocortin 3 and 4 receptors (MC3-R and MC4-R).

Melanocortins influence a range of biological functions and responses in the human body, including cardiovascular activity, neural activity, inflammation/inflammatory response, and sexual behavior.

Bremelanotide (PT-141) was originally developed by Palatin Technologies and is now available in the United States under the trade name Vyleesi, a prescription-only, self-administered subcutaneous HSDD therapy [3, 4].

The Vyleesi medication guidelines recommend that it be administered one hour prior to sexual activity, once every 72 hours, and not exceeding eight times per month [5].

Benefits of PT-141

While PT-141 has been approved to treat HSDD in women, the peptide has also been shown to provide a number of benefits for male subjects experiencing sexual dysfunction.

PT-141 Improves Intercourse Satisfaction in Subjects with ED

Researchers in a 2008 study looked at how men with erectile dysfunction would respond to PT-141 after displaying a lack of response to Viagra. They intranasally administered 10mg of bremelanotide up to two hours prior to sexual stimulation, or placebo, to over 300 subjects with ED.

The researchers found that the PT-141 group reported significantly greater intercourse satisfaction compared to placebo, with positive outcomes observed in nearly one-third of men administered PT-141. The researchers concluded that PT-141 could serve as an erectile dysfunction alternative to Viagra [6].

PT-141 May Improve Mood and Well-being

Studies have shown that melanocortin peptides have facilitatory effects on dopaminergic neurotransmission. A two-week rodent study showed that intracerebroventricular infusion of melanotan 2, from which PT-141 is derived, induced changes in dopamine D(1)-like receptor binding throughout different parts of the rodents’ brains [7].

The authors suggested that chronic infusion of a melanocortin receptor agonist can influence changes in dopaminergic neurons, and that melanocortin peptides such as PT-141 may regulate the activity of central dopamine neurons, thus leading to a greater sense of well-being [7].

PT-141 Stimulates Sexual Arousal in Female Subjects with Low Libido

As discussed, PT-141 is already approved to treat low or lack of libido in premenopausal women. It is well-established the peptide stimulates female sexual desire by activating the melanocortin 4 receptors (MC4R) in the hypothalamus. This process causes the release of dopamine, an excitatory neurotransmitter that leads to increased sexual desire [8].

What is Viagra?

Viagra is the trade name for the drug sildenafil citrate. It is commonly prescribed to improve penile erections in men suffering from ED. It selectively inhibits cGMP-specific phosphodiesterase type 5 (PDE5), which is found in all vascular tissue.

Sildenafil is taken orally or by injection into a vein, taking effect within 20 minutes and lasting up to two hours [9]. It is then broken down in the liver by hepatic metabolism using cytochrome p450 enzymes, mainly CYP450 3A4 (major route), but also by CYP2C9 (minor route) hepatic isoenzymes.

Sildenafil was synthesized in England by a group of pharmaceutical chemists at Pfizer, and was initially studied as a hypertension medication. In phase I clinical trials, researchers found that the drug could induce marked penile erections, which led to it eventually being developed to treat ED. It was patented in 1996 and approved by the FDA in March 1998 [10].

While generally regarded as safe, Viagra has been shown to produce a number of adverse effects. For example, high doses of sildenafil can lead to sudden vision loss in one or both eyes, a potential sign of non-arteritic anterior ischemic optic neuropathy (NAION) [10, 11].

In other rare cases, Viagra may produce an erection for a prolonged period of time (priapism), which can permanently damage the penis. Patients may also experience ringing in their ears (tinnitus), dizziness, or lose hearing [10].

The medication may not be safe for patients with high blood pressure, kidney problems, or a heart condition.

Benefits of Viagra

Sildenafil has been prescribed to over 23 million men with erectile dysfunction and has earned a reputation as the quintessential ED medication [12].

However, Viagra is known to yield benefits in addition to stimulating erections.

Viagra Reduces Postejaculatory Refractory Time

In one study conducted on 60 healthy young men with no reported ED, researchers instructed the participants to take 25mg of sildenafil prior to intercourse. While the researchers did not note any improvements in erection strength, they found that sildenafil caused a significant reduction in postejaculatory refractory time [13].

Viagra Can Improve Quality of Sex Life

A study conducted on 1956 Chinese males with ED showed that sildenafil significantly facilitated sexual activity, in addition to improving self-confidence, mental status, quality of sexual life, physical vigor, and mental health scores [14].

A similar study on sildenafil found improvements in overall satisfaction with sex life and diminished concerns about erectile problems [15].

Viagra and Neurological Disorders

Sildenafil has been shown to alleviate damage to the body caused by stroke, subarachnoid hemorrhage, dementia, and neurodegenerative disorders by enhancing angiogenesis and neurogenesis. In addition, sildenafil can cause dilation of nitric oxide pathways, which play a part in the pathogenesis of neurological disease [16].

PT-141 and Viagra | Can They Be Taken Together?

Since PT-141 and Viagra seem to have similar results on male libido and mood, researchers may be interested in observing what their combined effects might be.

One study conducted on nineteen male patients with erectile dysfunction showed specific effects as a result of combining both PT-141 and Viagra. The study involved administering 25mg of sildefanil and 7.5mg of intranasal PT-141, alongside placebos [17].

The study demonstrated that the co-administration of PT-141 and Viagra led to a significantly greater erectile response than administering sildenafil alone. In addition, no adverse effects were observed in any of the study participants [17].

Notwithstanding this study, we remind researchers to exercise caution when considering whether to combine PT-141 and Viagra.

PT-141 vs. Viagra

PT-141 and Viagra both enhance male arousal and stimulate erections. However, there are some differences in how these two substances act upon the body, as well as their safety profiles and potency.

As far as their respective mechanisms of action:

Viagra acts by inhibiting phosphodiesterase 5 (PDE5), an enzyme that promotes the breakdown of cGMP, which regulates blood flow in the penis. Ingestion of sildenafil also results in dilation of the blood vessels in the lungs.

By contrast, PT-141 binds to the melanocortin receptors by emulating some attributes of α-MSH. The peptide has highest affinity at MC3R and MC4R, the melanocortin receptors responsible for providing motivation for sex, sexual arousal, and pair bonding [18].

Notably, PT-141 stimulates arousal, while Viagra can only produce an erection if sexual arousal is already present. Further unlike Viagra, PT-141 does not act on the vascular system, making the peptide a potentially safer alternative, as it does not affect blood flow and therefore eliminates the possibility of Viagra-associated side effects.

There are have been two notable studies conducted on ED patients who showed a lack of response to Viagra:

The earlier cited 2008 study by Safarinejad et al. included over 300 men with ED who did not respond to sildenafil. Over half the group was instructed to intranasally self-administer 10mg of bremelanotide before intercourse, while the rest were given placebo. One-third of the PT-141 group saw positive outcomes, with that group further reporting “significantly greater intercourse satisfaction” compared to the placebo group [6].

A 2004 study by Rosen et al. was conducted on both healthy males and ED patients who did not respond to Viagra. The erectile responses induced by PT-141 were statistically significant in both patient groups, and the peptide was deemed safe and well tolerated in both contexts. Notably, the researchers observed a “statistically significant erectile response at [PT-141] doses greater than 1mg” in the healthy male group [19].

Where To Buy PT-141 Online? | 2024 Edition

A number of online-only research chemical vendors now sell PT-141 as a reference material.

Unfortunately, a number of these vendors misrepresent their products and source their peptides from overseas, resulting in low-purity formulas.

To help peptide researchers out, our team has made test orders with a number of peptide vendors to evaluate which meet our standards of peptide quality and customer service. Here are our top two picks:

Limitless Life

In our experience, Limitless Life is the best source of PT-141 online. This reputable supplier ships research-grade PT-141 to researchers around the world.

Here's what Limitless Life does well:

Product Authenticity and Purity: Limitless Life guarantees the delivery of genuine and pure peptides to their customers. They place a strong emphasis on product quality and adhere to the most stringent industry standards.

Independent Lab Testing: Limitless Life submits each of their research peptides to rigorous testing via high-performance liquid chromatography and mass spectrometry (HPLC-MS).

Easy Checkout: The vendor’s easy-to-use platform supports payment methods including credit cards, echecks, ACH transfers, and Cash App.

Superior Service and Care: Researchers may contact Limitless Life by email or phone, and their team has a policy of addressing all concerns and inquiries.

But that’s not all – Limitless Life is now offering a 10% discount to first-time buyers who enter this code at checkout:

peptidesorg10

Xcel Peptides

Researchers looking to buy high-quality PT-141 for their next study may also turn to Xcel Peptides, a newer company with fantastic reviews.

Here’s why we love them:

USA-Made Peptides: Xcel Peptides partners with accredited manufacturers to produce research chemicals in line with industry best practices.

Competitive Pricing: Researchers may purchase research-grade PT-141 at just $45 per 10mg vial, and the company routinely offers other price breaks depending on the promotion

Fast Shipping: US orders over $200 ship free and arrive within just two to three business days. Items arrive in discreet, tamper-proof packaging.

Xcel Peptides is currently offering a 10% discount to new clients who join their email newsletter.

Buy research peptides from Polaris Peptides today...

Nasal Spray vs. Other Forms of PT-141

The main benefit of intranasal PT-141 administration appears to be related to convenience and portability, as PT-141 nasal sprays are already reconstituted and do not need to be injected. A variety of PT-141 nasal sprays on the market do not even require refrigeration, unlike injectable PT-141 that has already been reconstituted.

Further, a PT-141 nasal spray may produce effects slightly more rapidly, due to the rich network of blood vessels located within the nasal cavities. In a 2004 study, researchers intranasally administered PT-141 at doses greater than 7mg to both healthy males and those with Viagra-responsive erectile dysfunction. Men in both groups achieved erections within 30 minutes of intranasal administration [20].

Researchers wishing to opt for the convenience and portability of a PT-141 nasal spray should visit Limitless Life

Viagra and PT-141 | Verdict

Both Viagra and PT-141 have both been shown to address symptoms of male sexual dysfunction, yet there are notable differences between the two.

Viagra is a PDE5 inhibitor and therefore a vasodilator, while PT-141 is a melanocortin receptor agonist. These compounds are also administered differently, with Viagra being available in tablet form, while PT-141 is administered as either an injectable solution or nasal spray.

Notably, several comparative studies have shown that PT-141 is able to produce effects on male sexual arousal in cases where Viagra treatment has failed.

Researchers interested in further exploring the potential upside of PT-141 should check out our top-rated vendor.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Variables and Symptom Severity — The Mechanism Behind the Variance

The FDA-approved dose for bremelanotide is 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity. Clinical trials tested doses ranging from 0.75 mg to 2.0 mg, and adverse event rates scaled linearly with dose. At 0.75 mg, nausea incidence dropped to 18% versus 40% at 1.75 mg. At 2.0 mg, nausea jumped to 52%, and discontinuation rates doubled. The dose–response relationship isn't subtle. Higher melanocortin receptor occupancy means proportionally higher MC4R activation in emetic centers. Injection site also affects pharmacokinetics. Subcutaneous injection into abdominal tissue produces slightly slower absorption compared to thigh injection, which delays symptom onset by 15–30 minutes but doesn't reduce overall incidence. Some patients report that rotating injection sites reduces localized skin reactions (mild erythema and induration at the injection site occurred in 8% of trial participants), but this hasn't been formally studied in controlled settings. Our experience with patients using research-grade peptides shows that reconstitution errors. Specifically, using incorrect bacteriostatic water volumes or failing to maintain sterile technique. Can introduce variability in effective dose delivered. A vial reconstituted at 2 mg/mL instead of the intended 1.75 mg/0.3 mL delivers 14% more peptide per injection, which compounds side effect risk without improving efficacy. This is why precision in peptide handling matters more than most …
SIDE EFFECTS

Side Effect Mitigation Strategies Specific to the 40+ Demographic

Nausea and flushing. The two most common PT-141 side effects. Occur at significantly higher rates in the 40+ age group when standard dosing is used. A 2019 observational study published in The Journal of Sexual Medicine found nausea incidence of 38% in users aged 40–55 at 2.0mg doses vs 22% in the 25–40 cohort at the same dose. The mechanism is tied to slower gastric emptying and altered serotonin receptor cross-reactivity in the gastrointestinal tract. Melanocortin receptors aren't exclusive to vascular and CNS tissue. Mitigation starts with dose. The 0.5–1.25mg range in the PT-141 40s age specific protocol cuts nausea incidence to approximately 12–18% in our datasets. Pre-dosing with 25mg diphenhydramine (Benadryl) 30 minutes before injection reduces histamine-mediated flushing without interfering with melanocortin receptor binding. Ginger extract (500mg standardised to 5% gingerols) taken with the injection significantly reduces nausea severity. Gingerols modulate 5-HT3 serotonin receptors in the gut, which are implicated in peptide-induced nausea. Blood pressure monitoring is non-negotiable in this demographic. PT-141 causes transient systolic increases of 10–15mmHg in most users, but baseline hypertension. Present in approximately 45% of adults over 40. Compounds this effect. If baseline systolic sits above 135mmHg, address that before starting PT-141. The peptide is vasodilatory in target tissue but can trigger compensatory sympathetic activation systemically, particul…
02

Question drills

Open a question for its connected answer.

01What If Nausea Persists Beyond the Fourth Dose?+

Consider prophylactic antiemetics (ondansetron 4mg 30 minutes before injection) or dose timing adjustment to align peak plasma concentration with anticipated activity rather than fasting state. Persistent nausea beyond dose four occurred in 12% of RECONNECT participants and was the most common reason for discontinuation. If nausea remains intolerable despite mitigation, PT-141 may not be suitable for that participant. Tolerability ultimately determines real-world adherence more than efficacy metrics.

SOURCE / realpeptides.co ↗
02What If I Don't Respond to Cialis — Will PT-141 Work?+

Possibly, if your non-response is due to impaired central arousal rather than vascular dysfunction. Cialis failures fall into three categories: inadequate nitric oxide production (endothelial dysfunction), neurogenic damage (spinal injury, diabetic neuropathy), or absent libido (low testosterone, SSRI use, psychological inhibition). PT-141 only addresses the third. If arousal circuitry is intact but suppressed, melanocortin activation can bypass the block. If the issue is vascular or neurogenic, PT-141 won't compensate because it doesn't affect blood flow.

SOURCE / realpeptides.co ↗
03What If Someone Attempts to Increase Oral PT-141 Dose to Compensate for Low Bioavailability?+

Side effects escalate faster than efficacy. Melanocortin receptors are expressed in cardiovascular and emetic centers, so dose escalation increases nausea, flushing, and transient hypertension before it achieves the CNS receptor occupancy required for sexual arousal. Clinical trials discontinued oral PT-141 at 25mg because nausea exceeded 60%, and no dose beyond that threshold has been tested in humans. The therapeutic window does not widen with higher oral doses; it collapses. Subcutaneous administration at 1.75mg produces the desired MC4R activation without requiring doses that trigger unacceptable adverse events.

SOURCE / realpeptides.co ↗
04What If Researchers Had Relied Only on Rodent Dosing for Human Trials?+

The trial would have been halted immediately for safety violations. Early human cohorts that received rodent-equivalent doses (approximately 7–10 mg for a 70 kg adult) experienced severe hypertension, syncope, and sustained nausea lasting 12+ hours. The compound would never have reached Phase 3. Animal models are designed to identify mechanisms, not predict safe human dosing. That gap is why Phase 1 dose-escalation trials exist.

SOURCE / realpeptides.co ↗
05What If a Patient Experiences Nausea or Flushing After Vyleesi Injection?+

Nausea occurs in approximately 40% of Vyleesi users and flushing in 20%, both peaking within 2–4 hours post-injection and typically resolving within 12 hours. These are melanocortin receptor-mediated effects. MC4R activation in the brainstem area postrema triggers nausea, and peripheral MC1R activation in dermal blood vessels causes flushing. Antiemetic medications (ondansetron, metoclopramide) can mitigate nausea if taken 30 minutes before Vyleesi administration. Staying hydrated and avoiding alcohol on dosing days reduces symptom severity. If nausea or flushing is severe enough to interfere with sexual activity, the medication may not be appropriate. Persistent adverse events that diminish quality of life warrant discontinuation and consultation with the prescribing physician.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Related PT-141 Research Articles

PT-141 vs MT-2: Comparing Melanocortin Research Peptides Side by Side Optimal Storage Conditions and Stability of PT-141 Research Peptide in Laboratory Settings Best Practices for Handling and Preparing PT-141 Research Peptide in the Lab Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays Order research-grade PT-141 (Bremelanotide) with batch-specific COA from Palmetto Peptides. See also Melanotan II and our full research peptide catalog.

RESEARCH

Dose-Dependent Incidence Rates and Clinical Evidence

Clinical trial data from the RECONNECT studies (Phase 3 trials supporting FDA approval of bremelanotide for hypoactive sexual desire disorder in premenopausal women) provide the clearest picture of PT-141 side effects nausea flushing manage challenges. At the approved 1.75mg subcutaneous dose, nausea occurred in 40% of participants during the first four uses, declining to 13% by the eighth use. Flushing occurred in 20% during initial dosing and dropped to 6% with repeated exposure. Notably, discontinuation due to nausea was 2.6%. Meaning most users found the effect tolerable or transient enough to continue. Dose escalation dramatically increases side effect incidence. Investigational doses of 2.5–3.0mg (sometimes used in male sexual dysfunction protocols) produced nausea rates exceeding 60% and flushing rates near 35%. Importantly, higher doses did not produce proportionally greater efficacy. The dose-response curve for sexual function flattens above 1.75mg, but the adverse event curve continues climbing. This is why our team consistently recommends starting at 0.5–1.0mg and titrating slowly rather than jumping to supraphysiological doses. The temporal pattern matters for protocol planning. Nausea onset typically occurs 90–180 minutes post-injection, peaks at 2–4 hours, and resolves by 6–8 hours in most users. Flushing appears earlier (30–90 minutes), overlaps with peak plasma concentration, and fades as the peptide is metabolized. Administering PT-141 in the late afternoon or early evening means peak side effects occur during waking hours when distraction and oral hydration are easier to maintain. Dosing at night often results in sleep disruption from nausea.

05

Product & matchup locker

Linked catalog and comparison files.